COVID-19 is still evolving and emerging XBB subvariants have been found to be even more transmissible than some previous variants and can evade prior immunity from COVID-19 infection and vaccination.1-3
Spikevax® (COVID-19 Vaccine, mRNA), is now FDA approved for patients 12+. SPIKEVAX® has been updated to help protect against the COVID-19 subvariants recommended in the June 2023 FDA VRBPAC.
Spikevax® is available in 2 presentations - single-dose vials and pre-filled syringes.4 Pre-filled syringes are ready to ship.
Spikevax is ready-to-use with no deep-freeze storage required4
•Ready-to-use formulation, no need to reconstitute4. •Once thawed, Spikevax can be stored refrigerated between 2°C to 8°C (36°F to 46°F) for up to 30 days prior to use4
IMPORTANT SAFETY INFORMATION
Contraindications
Do not administer SPIKEVAX® to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of SPIKEVAX®.
Warnings and Precautions
•Management of Acute Allergic Reactions: Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of SPIKEVAX®. •Myocarditis and Pericarditis: Postmarketing data demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following vaccination. The observed risk is highest in males 18 through 24 years of age. •Syncope (fainting): May occur in association with administration of injectable vaccines, including SPIKEVAX®. Procedures should be in place to avoid injury from fainting. •Altered Immunocompetence: Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished immune response to SPIKEVAX®. •Limitations of Vaccine Effectiveness: SPIKEVAX® may not protect all vaccine recipients.